Mangoceuticals has released “TRIM,” a compounded, oral dissolvable Tirzepatide tablet as an alternative to injectable therapies. Clinical trials have shown that Tirzepatide can deliver weight reductions of up to 20% in obese individuals. The phase 3 SURMOUNT-1 clinical trial showed that a significant percentage of participants achieved weight loss of over 15-20% in 72 weeks. According to Roots Analysis, the global GLP-1 market is projected to grow from $49.3B in 2024 to $157.5B by 2035, with the obesity segment expected to capture the majority share by 2035.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGRX:
- Mangoceuticals launches oral semaglutide for advanced weight loss treatment
- Mangoceuticals Raises Capital and Boosts CEO Perks
- Mangoceuticals files 16.17M shares of common stock for holders
- Mangoceuticals reports 1H revenue $377,258 vs. $241,959 last year
- Mangoceuticals receives patent in India, initiates clinical trials